[The antitumor activity of Shuang-Xi-Zuo-Wan-1 in C57/BL mice].
OBJECTIVE
To detect the antitumor activity of Shuang-Xi-Zuo-Wan-1(Eb), a novel organoselenium compound, in C57/BL mice transplanted with Lewis lung cancer(LLC).


METHODS
The LLC transplanted C57/BL mice model was established,and the mice were randomly divided into four groups, including high dose Eb group (25.0 mg/kg), low dose Eb group (12.5 mg/kg), positive control group (DDP, 2.0 mg/kg) and negative control group (solvent). Each group had twelve mice. Intraperitoneal injections (ip.) of four pharmaceuticals were performed once a day through the abdominal wall separately, from the second to the eighth days after cancer was transplanted. On the eleventh day, six mice of each group were killed and the influences of Eb on growth speed, size, weight, invasion, inhibitory rate, proliferation index and apoptosis rate of LLC were observed and calculated. The remaining mice were fed till all of them died naturally and the average survival time of each group was calculated.


RESULTS
Eb could inhibit the growth and infiltration of LLC (the cancer inhibitory rate of high does Eb was 80.31%) obviously and prolong the average survival time of these with mice cancer. After being given Eb, the nuclear of the cancer cell concentrated and the fission phase cells reduced. In addition,the number of apoptosis cancer cells increased.


CONCLUSIONS
The novel organoselenium compound Eb has antitumor activity in vivo. It can inhibit the growth and infiltration of LLC in mice, and induce the apoptosis of cancer cells.
Wang
Yi-rui
YR
Peking University School of Pharmaceutical Sciences, Beijing 100083, China.
Xiao
Jun-jun
JJ
Dong
Xiao-min
XM
Meng
Shu-cong
SC
Deng
Sheng-ju
SJ
Kuang
Bin
B
Yan
Jun
J
Zhao
Fang
F
Zeng
Hui-hui
HH
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D016566:Organoselenium Compounds / Q000627:therapeutic use*; D011897:Random Allocation
D000970:Antineoplastic Agents; D016566:Organoselenium Compounds